Drug Insight: aggrecanases as therapeutic targets for osteoarthritis
Amanda J Fosang* and Christopher B Little
Correspondence *University of Melbourne Department of Paediatrics and Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria 3052, Australia
Email amanda.fosang@mcri.edu.au
High concentrations of intact aggrecan are required for effective weight-bearing in healthy cartilage. Aggrecanases from the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) enzyme family, particularly ADAMTS-4 and ADAMTS-5, are thought to be involved in the pathogenesis of osteoarthritis. In this Review, Drs Fosang and Little discuss potential disease-modifying agents for osteoarthritis that could trigger the downregulation of ADAMTS enzymes.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Pathogenesis of arthritis: recent research progressNature Immunology News and Views (01 Sep 2001)
RESEARCH
Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritisNature Letters to Editor (31 Mar 2005)
See all 24 matches for Research